Prophylactic Medication for the Prevention of Endoscopic Recurrence in Crohn's Disease: A Prospective Study Based on Clinical Risk Stratification

Publication date

2023-02-01

Authors

Arkenbosch, Jeanine H.C.
Beelen, Evelien M.J.
Dijkstra, Gerard
Romberg-Camps, Mariëlle
Duijvestein, Marjolijn
Hoentjen, Frank
Van Der Marel, Sander
Maljaars, P. W.Jeroen
Jansen, Sita
De Boer, Nanne K.H.

Editors

Advisors

Supervisors

Document Type

Article

Collections

Open Access logo

License

cc_by_nc

Abstract

Background: To prevent recurrence after ileocolonic resection [ICR] in Crohn's disease [CD], postoperative prophylaxis based on risk stratification is recommended in international guidelines. This study aimed to evaluate postoperative CD recurrence after implementation of a clinical management algorithm and to determine the predictive value of clinical and histological risk factors [RFs]. Methods: In this multicentre, prospective cohort study, CD patients [≥16 years] scheduled for ICR were included. The algorithm advised no postoperative medication for low-risk patients, and treatment with prophylaxis [immunosuppressant/biological] for high-risk patients [≥1 RF: active smoking, penetrating disease, prior ICR]. Clinical and histological RFs [active inflammation, granulomas, plexitis in resection margins] for endoscopic recurrence [Rutgeerts' score ≥i2b at 6 months] were assessed using logistic regression and ROC curves based on predicted probabilities. Results: In total, 213 CD patients after ICR were included [age 34.5 years; 65% women] (93 [44%] low-risk; 120 [56%] high-risk: 45 [38%] smoking; 51 [43%] penetrating disease; 51 [43%] prior ICR). Adherence to the algorithm was 82% in low-risk [no prophylaxis] and 51% in high-risk patients [prophylaxis]. Endoscopic recurrence was higher in patients treated without prophylaxis than with prophylaxis in both low [45% vs 16%, p = 0.012] and high-risk patients [49% vs 26%, p = 0.019]. Clinical risk stratification including the prescription of prophylaxis corresponded to an area under the curve [AUC] of 0.70 (95% confidence interval [CI] 0.61-0.79). Clinical RFs combined with histological RFs increased the AUC to 0.73 [95% CI 0.64-0.81]. Conclusion: Adherence to this management algorithm is 65%. Prophylactic medication after ICR prevents endoscopic recurrence in low- and high-risk patients. Clinical risk stratification has an acceptable predictive value, but further refinement is needed.

Keywords

Crohn's disease, Ileocecal resection, postoperative recurrence, General Medicine

Citation

Arkenbosch, J H C, Beelen, E M J, Dijkstra, G, Romberg-Camps, M, Duijvestein, M, Hoentjen, F, Van Der Marel, S, Maljaars, P W J, Jansen, S, De Boer, N K H, West, R L, Horjus, C S, Stassen, L P S, Van Schaik, F D M, Van Ruler, O, Jharap, B J H, Visschedijk, M, Janssen, A, Erler, N S, Doukas, M, Ooms, A H A G, Kats-Ugurlu, G, Van Der Woude, C J & De Vries, A C 2023, 'Prophylactic Medication for the Prevention of Endoscopic Recurrence in Crohn's Disease : A Prospective Study Based on Clinical Risk Stratification', Journal of Crohn's and Colitis, vol. 17, no. 2, pp. 221-230. https://doi.org/10.1093/ecco-jcc/jjac128